I really don't want to be a doctor

Chapter 278 Drug R&D Progress
Shenzhou Biological Medicine Laboratory also showed full goodwill towards the three sudden new faces.

If the three of Lu Kequan don't know anything, the other R&D personnel of Shenzhou Lab will patiently teach them.

On the one hand, the experimental dogs in Shenzhou Laboratory are all young, unlike those old fritters who have been in the laboratory all year round, they are very concerned about these teaching matters; on the other hand, it is Jing Xiaoran's instruction to let them take care of Lu Kequan et al.

During this period of time, apart from treating patients in the hematology department, Jing Xiaoran's life is relaxed and comfortable, and he also has more spare time to go home and spend time with his parents, Xiaoxiao.

What pleased Jing Xiaoran the most was that the speed at which papers were produced by the Shenzhou Laboratory was really good.

The R&D team of "Immune Checkpoint Inhibitors" led by Zhu Xianqing published another SCI paper with an impact factor of 12 after the last published paper, and published it in the Oncology sub-journal of The Lancet superior.

It's only been two months since the last published paper!This has made many people in the industry have a strong interest in the Shenzhou Laboratory. The speed of producing papers can be said to be second to none in China. Many laboratories may not be able to publish so many SCI papers in a year, let alone Such a high-scoring, high-quality paper!
Of course, the reason for such a fast speed is all because of the existence of Jing Xiaoran.

Under his leadership, although Zhu Xianqing's research team has R&D bottlenecks, they break through quickly every time; if R&D goes in the wrong direction, Jing Xiaoran will correct it in time.

At this speed of "opening and hacking", the speed of research and development of "immune check inhibitors" by Sino Biopharmaceutical Laboratory has finally caught up with major European and American pharmaceutical companies.

"Xiao Ran, according to my estimation, the current research and development progress of pharmaceutical companies like Pfizer is almost at the same level as ours."

In the Shenzhou laboratory, Zhu Xianqing was holding the Lancet paper acceptance notice with a smile on his face.

"And if we continue to follow the current progress, the initial development of the drug will be completed within three months; and we will become the first laboratory in the world to develop an immune checkpoint inhibitor."

It has only been less than half a year since he came to Shenzhou Laboratory, and Zhu Xianqing has published many papers that he could not have imagined before, including SCI papers with more than 10 points.

Zhu Xianqing has been working at Pfizer for nearly ten years. He has indeed published many articles, but most of them are nominal, belonging to the fourth, fifth, or even the last.

But this time, it was Zhu Xianqing who signed an SCI paper with more than 10 points as the first author.

Zhu Xianqing felt like he had rejuvenated his career, and under the leadership of Jing Xiaoran, his enthusiasm for scientific research became more and more fierce.

The reason for this is all because the laboratory will make new discoveries every once in a while, which is the biggest incentive for scientific researchers.

Zhu Xianqing has already decided to move to Fancheng with his family, and found a house near the Shenzhou laboratory.

At the same time, let the wife and children also move here.In this way, he can concentrate more on scientific research.

"Three months?" Jing Xiaoran frowned. The development process of this "immune checkpoint inhibitor" was too cumbersome. He had tried his best to avoid detours in the experiment, but he didn't expect it would take so long.

What he is most afraid of now is that European and American pharmaceutical companies have developed drugs ahead of time, and everything he has done will be wasted.

"Yes, three months is already very short." Zhu Xianqing said, "It is absolutely impossible for foreign laboratories to be faster than us, but if the drug is successfully developed, our next step is..."

This so-called successful research and development is just a "drug" synthesized, but the drug has not been tested in human beings, and it is impossible for the drug to be put on the market for clinical use.

For research and development laboratories, there are usually two options for drug development to this point.

First, do not conduct clinical trials, and directly sell the drug to major manufacturers, so that you can earn a substantial patent transfer fee.

Doing so can avoid a situation where once a drug fails clinical trials and cannot be marketed, it means that all previous efforts are in vain, and the semi-finished drug is worthless.But they can avoid this loss by selling semi-finished drugs before that.

Second, the laboratory contacts the hospital on its own to conduct Phase IV clinical trials of the drug.Compared with the first method, the research and development cycle of this method is much longer, but once it is successful, the finished drug can be sold, and the patent transfer fee obtained is several times higher than that of the first method!
"Continue to do human clinical experiments." Jing Xiaoran said without hesitation.

He knew very well that the drug he produced would definitely pass the Phase IV clinical trial, so there was absolutely no need to resell the semi-finished drug to other pharmaceutical companies.

"Okay!" Zhu Xianqing appreciates Jing Xiaoran's courage. This choice is actually a bet, or he has full confidence in the drug he has developed. Otherwise, if the drug fails to pass the Phase IV clinical laboratory and the drug cannot be marketed, then It means that all the hard work is in vain, and research and development must be carried out again.

It's just that Zhu Xianqing didn't expect that, as a prophet, Jing Xiaoran already knew that the "immune checkpoint inhibitor" in their hands would definitely pass the clinical trial.

As for another experimental group, Jeffrey's "Mesenchymal Stem Cell" research and development group.

After the last paper was published, this experimental group has been silent for a long time, and this time it did not produce any SCI papers.

The main reason is that Jing Xiaoran is not very familiar with the field of "mesenchymal stem cells", so he can only occasionally mention Jeffrey to control the overall direction.

However, in some small research and development processes, he was unable to correct Jeffrey's mistakes in time, so that this was a detour taken by the experimental group.

Seeing that the experimental group next door has been publishing SCI papers, Hong Sheng was extremely depressed.

Since the last SCI paper was published, Hong Sheng has tasted the sweetness.

It's just that he didn't realize that he was only a junior student, and it was extremely rare to be named in a high-scoring SCI paper.

Lu Kequan has also been staying in the Shenzhou Laboratory during this time, and has some contacts with the two experimental groups of the laboratory.

Regarding Hong Sheng's idea, he was really speechless, because he himself had never been named in such a high-scoring SCI.

As for the paper published by Zhu Xianqing's "Immune Check Inhibitor" experimental group, Lu Kequan couldn't even think about it!

Not to mention the previous ones, let’s just say that the 12-point SCI paper published by Zhu Xianqing this time is enough for Lu Kequan to be promoted from attending doctor to chief doctor; and with this high-scoring paper in hand, even if he is not the first author, That is also very beneficial, and it will definitely be of great benefit to the application of some projects and funds!

At the same time, Lu Kequan was a little envious of the young people in the Shenzhou laboratory!
If he can have this kind of condition, why bother to be an attending doctor all the time?

(End of this chapter)